



WORKSHOP

V Simpósio Internacional da SPM

Ipanema Porto - Porto, 14 e 15 Outubro 2011

COMUNICAÇÕES LIVRES/POSTERS

Autor(es):

Ilda Rocha, Cátia Lourenço, Fátima Silva, Isabel Santos

Morada:

Rua Santa Rita nº3, 2º andar; 4430-219 Vila Nova de Gaia

Telefone:

227120336

Telemóvel:

919679732

E-mail:

ilda_j@hotmail.com

Título:

Autor que irá apresentar:

Ilda Rocha

Meios Audiovisuais:

Datashow

Slides

Projector multimédia

ZOLEDRONIC ACID 5 MG IN POSTMENOPAUSAL OSTEOPOROSIS' TREATMENT/PREVENTION – THE GYNAECOLOGY DEPARTMENT EXPERIENCE OF CHVNG/E

Objective: Evaluation of the risk factors for osteoporosis, as well as zoledronic acid 5mg indications, adverse reactions and tolerability in postmenopausal treatment/prevention of osteoporosis.

Methods: Patients included in this study were followed in the Menopausal Gynaecology outpatient clinic to whom zoledronic acid 5mg was administered for treatment/prevention of osteoporosis, between January 2009 and August 2011.

Results: The study group included 11 cases. The patients' mean age was 65,8 years (SD±10,448; maximum – 78; minimum – 49). The drug was ministered once in 63,6% (n=7), twice in 27,3% (n=3) and trice in 9,1% (n=1) of the patients. In all cases the intravenous administration time was >15min. There was osteoporosis in 81,2% (n=9) and osteopenia in 18,2% (n=2). History of bone fracture was present in 18.2% (n=2); 18,2% (n=2) were smokers; and 9,1% (n=1) were at risk for falls. Each patient received a combined administration of Calcium and Vitamin D. In 1 case (9,1%) side effects were reported: nausea, aerocoly and eructations.

Conclusions: Zoledronic acid is indicated for the treatment of osteoporosis and its prevention in patients with osteopenia. Adverse reactions are rare and non specific, usually without need of further treatment. The drug presents a good tolerability and efficacy as shown in the literature.

Preferência de apresentação:

Poster

Comunicação livre

Deve enviar resumo, juntamente com 2 cópias até 15 Setembro para:
intsym2011@socportmenopausa.mail.pt